HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Cabasso, V. J. Articles by Stebbins, M. R. Search for Related Content PubMed PubMed Citation Articles by Cabasso, V. J. Articles by Stebbins, M. R.

Measles and Poliovirus Antibodies in Commercial Preparations of Human -Globulin

From the Viral and Rickettsial Research and Biological Production Section, Lederle Laboratories, American Cyanamid Company, Pearl River, New York

Abstract

Twenty-three lots of commercial preparations of human -globulin (GG) derived from placental extracts were titrated in HeLa cell cultures for antibodies neutralizing measles virus, with cytopathology serving as an end point indicator. Titers of the various lots ranged between 10^-2.70 and 10^-3.30/0.1 ml of GG, giving a 4-fold difference between the lowest and highest titer. Repeated titrations of two "low" and two "high" titered lots indicated this difference to be highly significant.

Fifteen of the 23 lots were also titrated for the three types of poliomyelitis antibodies by the metabolism-inhibition test in the presence of monkey kidney cells. Titers ranged between 10^-3.91 and 10^-4.39/0.25 ml of GG for type I, between 10^-4.09 and 10^-4.70 for type II, and 10^-3.79 and 10^-4.39 for type III, which parallels the seroepidemiological pattern of the types of poliomyelitis in the U.S.A. The variation between the highest and lowest poliomyelitis titers obtained was similar to that for measles, being 3-fold for type I and 4-fold for types II and III.

The application of these findings to the eventual establishment of minimum requirements for the release of commercial lots of GG is discussed.